ETF Holdings Breakdown of TRDA

TRDA institutional holdings

The following institutional investment holdings of TRDA have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	26,307	USD 202,564 5.7%	7.70
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	26,307	USD 202,564 5.7%	7.70
Total =		52,614	USD 405,128

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with TRDA

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $25.67 Average Price Target from Brokerages

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) has received an average recommendation of “Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-09-12 02:01:10

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,935 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $52,012.50. Following the sale, the insider directly owned 1,093,313 shares of the […] - 2025-07-14 06:12:51

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 20,065 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Ventures V. L.P. 5Am sold 20,065 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $150,487.50. Following the completion of the transaction, the insider owned 3,163,066 shares of […] - 2025-07-14 05:38:49

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) Director Kush Parmar sold 27,000 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $202,500.00. Following the sale, the director owned 1,093,313 shares in the company, valued at […] - 2025-07-14 05:38:48

Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% – Should You Sell?

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) fell 3.6% during mid-day trading on Monday . The company traded as low as $6.87 and last traded at $6.97. 149,403 shares traded hands during trading, an increase of 11% from the average session volume of 134,750 shares. The stock had previously closed at $7.23. […] - 2025-07-08 04:35:07

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 152.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 35,750 shares of the company’s stock after acquiring an additional 21,594 shares during […] - 2025-06-12 05:12:44

First Trust Advisors LP Cuts Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

First Trust Advisors LP decreased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 9.6% during the fourth quarter, HoldingsChannel reports. The firm owned 73,749 shares of the company’s stock after selling 7,800 shares during the period. First Trust Advisors LP’s holdings in Entrada Therapeutics were worth $1,275,000 at the end […] - 2025-05-08 05:54:57

Barclays PLC Has $887,000 Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Barclays PLC grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 13.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,365 shares of the company’s stock after purchasing an additional 6,255 shares during the period. Barclays PLC’s holdings in […] - 2025-05-06 04:40:49

Geode Capital Management LLC Cuts Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Geode Capital Management LLC trimmed its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 573,891 shares of the company’s stock after selling 2,560 shares during […] - 2025-04-23 05:06:55

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.

Federated Hermes Inc. boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 3,104.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,814 shares of the company’s stock after purchasing an additional 96,699 shares during the period. Federated Hermes Inc. owned about […] - 2025-04-15 04:54:50

Arrowstreet Capital Limited Partnership Has $3.85 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Arrowstreet Capital Limited Partnership increased its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 123.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,520 shares of the company’s stock after acquiring an additional 122,823 shares during the quarter. Arrowstreet Capital […] - 2025-04-09 05:30:53

AlphaQuest LLC Invests $70,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

AlphaQuest LLC purchased a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 4,046 shares of the company’s stock, valued at approximately $70,000. A number of other large investors have also recently made changes to their positions in TRDA. Janus Henderson Group PLC […] - 2025-03-20 06:12:50

Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 66.39% from the company’s previous close. TRDA has been […] - 2025-02-27 06:44:55

China Universal Asset Management Co. Ltd. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

China Universal Asset Management Co. Ltd. bought a new position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 7,931 shares of the company’s stock, valued at approximately $137,000. A number of other […] - 2025-02-04 07:03:05

Back to Listing

Disclaimer